Comparing two types of dextrose injections for knee osteoarthritis treatment
Comparative Efficacy of Intra-articular vs. MRI-guided Extra-articular Dextrose Injections in Knee Osteoarthritis Management
This study is testing whether a special type of knee injection guided by MRI works better than a standard injection for people aged 45 to 80 with knee osteoarthritis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 45 Years to 80 Years |
| Sex | All |
| Sponsor | Shin Kong Wu Ho-Su Memorial Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06755697 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of intra-articular versus MRI-guided extra-articular dextrose injections for managing knee osteoarthritis. Participants aged 45 to 80 who meet specific criteria will receive either type of injection to determine which approach yields better outcomes. The study aims to assess the benefits of targeting MRI-positive lesion sites compared to standard intra-articular injections. By utilizing MRI for precise targeting, the researchers hope to enhance treatment efficacy for knee osteoarthritis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 45 to 80 with knee osteoarthritis who meet specific clinical criteria.
Not a fit: Patients with severe systemic disorders, recent knee injections, or those who are not suitable for MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients suffering from knee osteoarthritis.
How similar studies have performed: While there is evidence supporting the use of dextrose injections for knee osteoarthritis, this specific comparison of intra-articular versus MRI-guided extra-articular injections is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. . age between 45 to 80 years old; 2. . meet at least three of the six American College of Rheumatology (ACR) criteria, including age over 50 years, morning stiffness less than 30 minutes, crepitus in passive knee movements, bony tenderness, bony enlargement, and no palpable warmth; 3. . radiologic grading of 2 or 3 according to Kellgren-Lawrence criteria; 4. showing willingness to receive prolotherapy. Exclusion Criteria: 1. . severe systemic disorders including cancer, uncontrolled diabetes mellitus, sepsis, or cardiopulmonary diseases; 2. . history of anticoagulation therapy, knee injection over the past three months; 3. . history of knee surgery or candidates for knee arthroplasty; 4. . history of drug abuse; 5. . a history of intolerance to prolotherapy; 6. . pregnancy; 7. . infectious arthritis, inflammatory joint diseases, joint dysplasia; 8. Body Mass Index (BMI) greater than 35 kg/m2; 9. . not suitable or no willing to received MRI examination of the knee.
Where this trial is running
Taipei
- Shin Kong Wu Ho-Su Memorial Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: Lin-Fen Hsieh — Shin Kong Wu Ho-Su Memorial Hospital
- Study coordinator: Lin-Fen Hsieh
- Email: M001026@ms.skh.org.tw
- Phone: +886-28332211
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.